A short, easily taught psychotherapy for borderline personality disorder appears to keep working long after the sessions stop. In a randomized controlled trial published in the journal Borderline Personality Disorder and Emotion Dysregulation, patients who received four months of brief Good Psychiatric Management, a streamlined intervention built around ten treatment sessions, showed a significantly greater reduction in clinician-rated borderline symptoms over 16 months than patients who received treatment as usual. The finding matters because structured psychotherapy is the first-line treatment for the condition, yet demand for such care far outstrips supply, leaving many patients waiting for help that brief, scalable treatments might deliver sooner.
The study, conducted between January 2019 and October 2023 at a university psychiatry department outpatient clinic in French-speaking Europe, enrolled 76 patients with borderline personality disorder at intake. Fifty of the participants, or 66 percent, were women, and their ages ranged from 18 to 60, with a mean age of 33. Patients were randomized into two conditions: 35 received brief Good Psychiatric Management and 41 received treatment as usual. Unlike many trials in this field, the sample included a relatively high proportion of male patients, roughly one third, which the authors note may offer a broader picture of follow-up effects than studies that are typically composed of more than 80 percent women.
Good Psychiatric Management was designed specifically to close the gap between the number of patients who need care and the number who can access it. It is a clinically derived treatment that blends cognitive-behavioral and psychodynamic strategies and emphasizes awareness of borderline functioning and interpersonal hypersensitivity. In the trial, six principles were implemented at every session: therapist activity and structuring, therapist support, a focus on life situations and relationships outside of the session, therapist relationship interventions, an explicit expectation of change, and fostering the patient’s accountability. Treatment included communicating the diagnosis and comorbidities, elaborating links between problem areas such as dependency, self-harming behavior and anger, working on treatment goals, and discussing behaviors that interfere with treatment. The final session involved synthesizing main achievements and deciding on next steps.
The comparison condition was deliberately minimal. Treatment as usual consisted of non-specific crisis management intervention following minimal ethical standards and guidelines of good medical practice, an approach the ethics committee approved as relying on common factors. Psychotropic medication was allowed, but discussion of borderline personality disorder specifics was prohibited. The same therapists treated participants in both arms, and adherence to Good Psychiatric Management principles was assessed with a dedicated questionnaire to ensure the interventions did not overlap. Twenty-eight therapists, 23 psychiatrists and 5 psychologists with an average of four years of clinical experience, delivered the treatments after receiving at least one day of intensive workshop training in the method.
Researchers assessed each patient at four time points: intake, two months, discharge at four months, and a one-year follow-up conducted 16 months after intake. The primary instrument was the Zanarini Rating Scale for Borderline Personality Disorder, a clinician-administered measure of nine diagnostic criteria scored from 0 to 4 for a potential total of 36 points, with items grouped into affective, cognitive, impulsive and relationship subscales. For reference, the mean score in a population with borderline personality disorder is 14.3, while a non-BPD population averages 5.2. Inter-rater reliability at intake was high, with an intraclass correlation coefficient of 0.857. As a secondary outcome, the team also examined medical files for the year after discharge to record whether patients had any consultation or hospitalization within the university clinic.
To model symptom change over the full period, the researchers used latent growth curve models estimated with robust maximum likelihood and multiple imputation across 50 datasets to handle a relatively high amount of missing data. The total Zanarini score declined significantly in both groups, but the decline was significantly steeper for the Good Psychiatric Management group, with a difference in mean slope of 1.166 points favoring the brief treatment. Patients in that group lost more than two points on average between each time point, compared with more than one point per interval for treatment as usual. Notably, the variance of the slope was not significant in either group, suggesting that scores decreased in a similar way for most patients rather than for only a subset.
Breaking the total score into its components revealed where the improvement was concentrated. On the cognitive problems subscale, which covers symptoms such as identity disturbance and dissociation, only patients in the Good Psychiatric Management group showed a significant decrease, losing almost half a point on average between each time point, while the treatment-as-usual group showed no significant change. The difference between groups in the rate of change fell just short of the significance threshold. On the affective subscale, covering symptoms such as inappropriate anger, mood reactivity and feelings of emptiness, both groups improved significantly, though the difference in change between groups was not significant. The models for the impulsivity and relationship subscales showed poor fit to the data, so their parameter estimates were not interpreted.
The authors caution that the groups did not start from identical positions. Despite randomization, patients assigned to Good Psychiatric Management had significantly higher baseline scores on the total scale and significantly more affective problems at intake, which means they stood to gain more from treatment from the start. This makes the results harder to interpret, and the team lists it among the study’s main limitations alongside the substantial missing data, which arose because some participants could not be reached or declined later assessments. The imputation procedures required to offset attrition may introduce biases that the study could not control, and the Zanarini scale was the only measure the researchers could reliably obtain at the one-year follow-up.
On the secondary outcome, the picture was more equivocal. Neither group was more likely than the other to use health services in the year following the end of treatment, with no significant differences in consultations or hospitalizations. The authors note that the study does not specify whether service use was directly due to borderline symptoms, since patients with the disorder often present with other mental health comorbidities that lead them to seek care. They speculate that patients who received the brief treatment may have become more confident in seeking help earlier in a period of distress, while the higher dropout rate in the comparison group may have left some patients less trusting of the health care system, though these possibilities remain untested.
The overall conclusion is that the effects of brief treatment were strengthened in both groups after one year, but that brief Good Psychiatric Management gave patients a specific advantage in continuing to progress after the intervention ended, potentially helping to diminish the societal burden of the disorder. Because the treatment requires only rapid and inexpensive training, the authors suggest that low-training interventions could be useful in mental health services, lowering the cost of targeted care. Still, the findings are tentative given the high amount of missing data and need replication. The researchers also emphasize that the study focused on symptom change rather than functioning, and they call for future work to assess both, along with the specific types and extent of services patients use after discharge.
Subject of Research: Follow-up effects of a brief Good Psychiatric Management intervention for borderline personality disorder compared with treatment as usual in a randomized controlled trial
Article Title: Follow-up effects of a brief Good Psychiatric Management treatment for borderline personality disorder
Article References: Blanco Machinea, J., Grandjean, L., Beuchat, H., Kolly, S., Conus, P., de Roten, Y., André, J., Tissot, H., & Kramer, U. (2026). Follow-up effects of a brief Good Psychiatric Management treatment for borderline personality disorder. Borderline Personality Disorder and Emotion Dysregulation, 13(1), Article 34. https://doi.org/10.1186/s40479-026-00357-z
Image Credits: AI Generated
DOI: 10.1186/s40479-026-00357-z
Keywords: borderline personality disorder, Good Psychiatric Management, randomized controlled trial, ZAN-BPD, follow-up, psychotherapy, treatment as usual, symptom reduction, latent growth curve model, mental health services, effects, brief
News Source: Glenn Wilkins. (November 6, 2026). Brief Good Psychiatric Management keeps easing borderline symptoms a year after treatment ends. Scienmag.
